Clinical Trials Logo

Necrotizing Fascitis clinical trials

View clinical trials related to Necrotizing Fascitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT06249971 Completed - Burns Clinical Trials

A Single-stage Bilayered Skin Reconstruction With Glyaderm®

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

The study will explore the potential of utilizing Glyaderm® in a single-stage engrafting process, aiming for a more cost-effective approach. While the absence of the reticular dermal layer is a challenge associated with autologous split-thickness skin grafting (STSG), often leading to hypertrophic scars and contractures, various dermal substitutes with inconsistent results exist. Bilayered skin reconstruction using glycerolized acellular dermis (Glyaderm®) has shown promise in improving scar quality through a two-step procedure. However, unlike the typical two-step process required for most dermal substitutes, our investigation focuses on the cost-effective application of Glyaderm® in a single-stage engrafting. This approach, if successful, could offer advantages such as reduced costs, shorter hospitalization times, and lower infection rates-attributes preferred by many surgeons, especially when autografts are available.

NCT ID: NCT05883033 Not yet recruiting - Clinical trials for Necrotizing Fascitis

VAC and Conventional Dressing in the Healing Process of Necrotizing Fasciitis

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Find out the best management of Necrotizing Fasciitis after surgical debridement

NCT ID: NCT04831112 Completed - Wound Infection Clinical Trials

Compare Effects of Dressing With Honey and EUSOL

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

Honey is super saturated solution containing sugar derived from nectar gathered by honeybee. Honey is viscus supersaturated solution mainly composed of sugar and water along with minor constituents such as minerals, vitamins, amino acids, organic acids, flavonoids, and other phenolic compound and aromatic substances. Honey contents according to percentages are fructose 38.6%, glucose 31%, water 17%, lactose 7.2%, larger sugars 4.7% and rest of micronutrients and elemental compounds are 1.5%. Honey enhances wound healing by removing slough and necrotic tissue from wound. It promotes wound healing by increasing angiogenesis, granulation and epithelization. Honey possess antimicrobial activity against bacteria like methicillin resistant staphylococcus aureus, vancomycin resistant Escherichia Coli, pseudomonas aeruginosa, and many other species. It also has activity against some yeast species such as aspergillus and penicillium. Honey used for dressing will be 'Langnese Honey". Langnese honey is raw honey / unprocessed packed as collected, quality and quantity will be same for patients.

NCT ID: NCT03147352 Completed - Clinical trials for Necrotizing Soft Tissue Infection

Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study

ProTreat
Start date: February 2013
Phase:
Study type: Observational [Patient Registry]

The investigators will analyze biomarkers related to the prognosis and treatment of necrotizing soft tissue infections (NSTI). The focus will be on whether certain endothelial and immune system biomarkers can function as markers of disease severity, mortality as well as the effects of hyperbaric oxygen therapy (HBOT). Biomarkers will be measured upon admission to an intensive care unit at Copenhagen University Hospital and during the following 3 days.